Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
Identifieur interne : 004444 ( Main/Exploration ); précédent : 004443; suivant : 004445Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
Auteurs : YUXIAN HE [États-Unis] ; JINGJING LI [États-Unis] ; LANYING DU [République populaire de Chine] ; XUXIA YAN [États-Unis] ; GUANEAN HU [République populaire de Chine] ; YUSEN ZHOU [République populaire de Chine] ; SHIBO JIANG [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is considered as a major antigen for vaccine design. We previously demonstrated that the receptor-binding domain (RBD: residues 318-510) of S protein contains multiple conformation-dependent neutralizing epitopes (Conf I to VI) and serves as a major target of SARS-CoV neutralization. Here, we further characterized the antigenic structure in the RBD by a panel of novel mAbs isolated from the mice immunized with an inactivated SARS-CoV vaccine. Ten of the RBD-specific mAbs were mapped to four distinct groups of conformational epitopes (designated Group A to D), and all of which had potent neutralizing activity against S protein-pseudotyped SARS viruses. Group A, B, C mAbs target the epitopes that may overlap with the previously characterized Conf I, III, and VI respectively, but they display different capacity to block the receptor binding. Group D mAb (S25) was directed against a unique epitope by its competitive binding. Two anti-RBD mAbs recognizing the linear epitopes (Group E) were mapped to the RBD residues 335-352 and 442-458, respectively, and none of them inhibited the receptor binding and virus entry. Surprisingly, most neutralizing epitopes (Groups A to C) could be completely disrupted by single amino acid substitutions (e.g., D429A, R441A or D454A) or by deletions of several amino acids at the N-terminal or C-terminal region of the RBD; however, the Group D epitope was not sensitive to the mutations, highlighting its importance for vaccine development. These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV, and this panel of novel mAbs can be used as tools for studying the structure of S protein and for guiding SARS vaccine design.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000482
- to stream PascalFrancis, to step Curation: 000508
- to stream PascalFrancis, to step Checkpoint: 000467
- to stream Main, to step Merge: 004668
- to stream Main, to step Curation: 004444
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine</title>
<author><name sortKey="Yuxian He" sort="Yuxian He" uniqKey="Yuxian He" last="Yuxian He">YUXIAN HE</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jingjing Li" sort="Jingjing Li" uniqKey="Jingjing Li" last="Jingjing Li">JINGJING LI</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lanying Du" sort="Lanying Du" uniqKey="Lanying Du" last="Lanying Du">LANYING DU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xuxia Yan" sort="Xuxia Yan" uniqKey="Xuxia Yan" last="Xuxia Yan">XUXIA YAN</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guanean Hu" sort="Guanean Hu" uniqKey="Guanean Hu" last="Guanean Hu">GUANEAN HU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yusen Zhou" sort="Yusen Zhou" uniqKey="Yusen Zhou" last="Yusen Zhou">YUSEN ZHOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shibo Jiang" sort="Shibo Jiang" uniqKey="Shibo Jiang" last="Shibo Jiang">SHIBO JIANG</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0337481</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0337481 INIST</idno>
<idno type="RBID">Pascal:06-0337481</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000482</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000508</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000467</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000467</idno>
<idno type="wicri:doubleKey">0264-410X:2006:Yuxian He:identification:and:characterization</idno>
<idno type="wicri:Area/Main/Merge">004668</idno>
<idno type="wicri:Area/Main/Curation">004444</idno>
<idno type="wicri:Area/Main/Exploration">004444</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine</title>
<author><name sortKey="Yuxian He" sort="Yuxian He" uniqKey="Yuxian He" last="Yuxian He">YUXIAN HE</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jingjing Li" sort="Jingjing Li" uniqKey="Jingjing Li" last="Jingjing Li">JINGJING LI</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lanying Du" sort="Lanying Du" uniqKey="Lanying Du" last="Lanying Du">LANYING DU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xuxia Yan" sort="Xuxia Yan" uniqKey="Xuxia Yan" last="Xuxia Yan">XUXIA YAN</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guanean Hu" sort="Guanean Hu" uniqKey="Guanean Hu" last="Guanean Hu">GUANEAN HU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yusen Zhou" sort="Yusen Zhou" uniqKey="Yusen Zhou" last="Yusen Zhou">YUSEN ZHOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shibo Jiang" sort="Shibo Jiang" uniqKey="Shibo Jiang" last="Shibo Jiang">SHIBO JIANG</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigenic determinant</term>
<term>Identification</term>
<term>Neutralizing antibody</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Identification</term>
<term>Déterminant antigénique</term>
<term>Protéine</term>
<term>Vaccin</term>
<term>Anticorps neutralisant</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is considered as a major antigen for vaccine design. We previously demonstrated that the receptor-binding domain (RBD: residues 318-510) of S protein contains multiple conformation-dependent neutralizing epitopes (Conf I to VI) and serves as a major target of SARS-CoV neutralization. Here, we further characterized the antigenic structure in the RBD by a panel of novel mAbs isolated from the mice immunized with an inactivated SARS-CoV vaccine. Ten of the RBD-specific mAbs were mapped to four distinct groups of conformational epitopes (designated Group A to D), and all of which had potent neutralizing activity against S protein-pseudotyped SARS viruses. Group A, B, C mAbs target the epitopes that may overlap with the previously characterized Conf I, III, and VI respectively, but they display different capacity to block the receptor binding. Group D mAb (S25) was directed against a unique epitope by its competitive binding. Two anti-RBD mAbs recognizing the linear epitopes (Group E) were mapped to the RBD residues 335-352 and 442-458, respectively, and none of them inhibited the receptor binding and virus entry. Surprisingly, most neutralizing epitopes (Groups A to C) could be completely disrupted by single amino acid substitutions (e.g., D429A, R441A or D454A) or by deletions of several amino acids at the N-terminal or C-terminal region of the RBD; however, the Group D epitope was not sensitive to the mutations, highlighting its importance for vaccine development. These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV, and this panel of novel mAbs can be used as tools for studying the structure of S protein and for guiding SARS vaccine design.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Yuxian He" sort="Yuxian He" uniqKey="Yuxian He" last="Yuxian He">YUXIAN HE</name>
</region>
<name sortKey="Jingjing Li" sort="Jingjing Li" uniqKey="Jingjing Li" last="Jingjing Li">JINGJING LI</name>
<name sortKey="Shibo Jiang" sort="Shibo Jiang" uniqKey="Shibo Jiang" last="Shibo Jiang">SHIBO JIANG</name>
<name sortKey="Xuxia Yan" sort="Xuxia Yan" uniqKey="Xuxia Yan" last="Xuxia Yan">XUXIA YAN</name>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Lanying Du" sort="Lanying Du" uniqKey="Lanying Du" last="Lanying Du">LANYING DU</name>
</noRegion>
<name sortKey="Guanean Hu" sort="Guanean Hu" uniqKey="Guanean Hu" last="Guanean Hu">GUANEAN HU</name>
<name sortKey="Yusen Zhou" sort="Yusen Zhou" uniqKey="Yusen Zhou" last="Yusen Zhou">YUSEN ZHOU</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004444 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004444 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:06-0337481 |texte= Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine }}
This area was generated with Dilib version V0.6.33. |